Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma

Takahiro Osawa, Takahiro Kojima, Tomohiko Hara, Mikio Sugimoto, Masatoshi Eto, Ario Takeuchi, Keita Minami, Yasutomo Nakai, Kosuke Ueda, Michinobu Ozawa, Motohide Uemura, Yasuyuki Miyauchi, Kojiro Ohba, Toshiro Suzuki, Satoshi Anai, Tetsuya Shindo, Naohisa Kusakabe, Keita Tamura, Motokiyo Komiyama, Takayuki GotoAkira Yokomizo, Naoki Kohei, Akira Kashiwagi, Masaya Murakami, Tomokazu Sazuka, Hiroaki Yasumoto, Hideto Iwamoto, Koji Mitsuzuka, Daichi Morooka, Toru Shimazui, Yoshiaki Yamamoto, Suguru Ikeshiro, Hiroshi Nakagomi, Ken Morita, Ryotaro Tomida, Tango Mochizuki, Takamitsu Inoue, Hiroshi Kitamura, Shuhei Yamada, Yoichi M. Ito, Sachiyo Murai, Hiroyuki Nishiyama, Nobuo Shinohara

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

The present study aimed to evaluate the efficacy of the real-world use of axitinib and to develop a prognostic model for stratifying patients who could derive long-term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split-sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 months in the entire study population, whereas it was not reached, 27 months, and 14 months in the favorable, intermediate, and poor risk groups, respectively, according to the new risk classification model. The following 4 variables were included in the final risk model: the disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio. The adjusted area under the curve values of the new model at 12, 36, and 60 months were 0.77, 0.82, and 0.82, respectively. The efficacy of axitinib in routine practice is comparable or even superior to that reported previously. The patients in the new model’s favorable risk group might derive a long-term survival benefit from axitinib treatment.

Original languageEnglish
Pages (from-to)2460-2471
Number of pages12
JournalCancer Science
Volume111
Issue number7
DOIs
Publication statusPublished - Jul 1 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this